A novel lentiviral vector targets gene transfer into human hematopoietic stem cells in marrow from patients with bone marrow failure syndrome and in vivo in humanized mice

Blood

Volumn 119, Issue 5, 2012, Pages 1139-1150

  Frecha, Cecilia ^a,b,c   Costa, Caroline ^a,b,c   Nègre, Didier ^a,b,c   Amirache, Fouzia ^a,b,c   Trono, Didier ^d   Rio, Paula ^e   Bueren, Juan ^e   Cosset, François Loïc ^a,b,c   Verhoeyen, Els ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d EPFL   (Switzerland)

^e CIEMAT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; LENTIVIRUS VECTOR; VIRUS GLYCOPROTEIN;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW DEPRESSION; CONTROLLED STUDY; EX VIVO STUDY; FANCONI ANEMIA; GENE TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; INOCULATION; MONONUCLEAR CELL; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; T LYMPHOCYTE; UMBILICAL CORD BLOOD; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84856594376     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-346619     Document Type: Article

References (49)

1. Aiuti A, Slavin S, Aker M, et al. Correction of ADASCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296(5577):2410-2413. (Pubitemid 34734219)
2. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346(16):1185-1193. (Pubitemid 34984579)
3. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326(5954):818-823.
4. Ahmed F, Ings SJ, Pizzey AR, et al. Impaired bone marrow homing of cytokine-activated CD34+ cells in the NOD/SCID model. Blood. 2004;103(6):2079-2087. (Pubitemid 38326223)
5. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283(5403):845-848.
6. Chitteti BR, Cheng YH, Poteat B, et al. Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function. Blood. 2010;115(16):3239-3248.
7. Croop JM, Cooper R, Fernandez C, et al. Mobilization and collection of peripheral blood CD34+cells from patients with Fanconi anemia. Blood. 2001;98(10):2917-2921.
8. Jacome A, Navarro S, Rio P, et al. Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Mol Ther. 2009;17(6):1083-1092.
9. Larghero J, Marolleau JP, Soulier J, et al. Hematopoietic progenitor cel harvest and functionality in Fanconi anemia patients. Blood. 2002;100(8):3051.
10. Tolar J, Adair JE, Antoniou M, et al. Stem cell gene therapy for fanconi anemia: report from the 1st international fanconi anemia gene therapy working group meeting. Mol Ther. 2011;19(7):1193-1198.
11. Orford KW, Scadden DT. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet. 2008;9(2):115-128.
12. Amsellem S, Ravet E, Fichelson S, Pflumio F, Dubart-Kupperschmitt A. Maximal lentivirus-mediated gene transfer and sustained transgene expression in human hematopoietic primitive cells and their progeny. Mol Ther. 2002;6(5):673-677. (Pubitemid 35363700)
13. Verhoeyen E, Wiznerowicz M, Olivier D, et al. Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood. 2005;106(10):3386-3395. (Pubitemid 41609172)
14. Kimura S, Roberts AW, Metcalf D, Alexander WS. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A. 1998;95(3):1195-1200. (Pubitemid 28124935)
15. Luens KM, Travis MA, Chen BP, Hill BL, Scollay R, Murray LJ. Thrombopoietin, kit ligand, and flk2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34+Thy-1+Lin- cells with preserved ability to engraft SCID-hu bone. Blood. 1998;91(4):1206-1215. (Pubitemid 28086873)
16. Coil DA, Miller AD. Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J Virol. 2004;78(20):10920-10926. (Pubitemid 39299632)
17. Sandrin V, Boson B, Salmon P, et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood. 2002;100(3):823-832. (Pubitemid 34832607)
18. Di Nunzio F, Piovani B, Cosset FL, Mavilio F, Stornaiuolo A. Transduction of human hematopoietic stem cells by lentiviral vectors pseudotyped with the RD114-TR chimeric envelope glycoprotein. Hum Gene Ther. 2007;18(9):811-820. (Pubitemid 47502847)
19. Relander T, Johansson M, Olsson K, et al. Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells. Mol Ther. 2005;11(3):452-459. (Pubitemid 40277322)
20. Maurice M, Verhoeyen E, Salmon P, Trono D, Russell SJ, Cosset FL. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood. 2002;99(7):2342-2350. (Pubitemid 34525419)
21. Frecha C, Levy C, Costa C, et al. Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J Virol. 2011;85(12):5975-5985.
22. Szécsi J, Drury R, Josserand V, et al. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther. 2006;14(5):735-744. (Pubitemid 44480752)
23. Frecha C, Costa C, Levy C, et al. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood. 2009;114(15):3173-3180.
24. Mantel C, Hendrie P, Broxmeyer HE. Steel factor regulates cell cycle asymmetry. Stem Cells. 2001;19(6):483-491. (Pubitemid 33095843)
25. Korin YD, Zack JA. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol. 1998;72(4):3161-3168. (Pubitemid 28175559)
26. Cumming RC, Lightfoot J, Beard K, Youssoufian H, O'Brien PJ, Buchwald M. Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat Med. 2001;7(7):814-820. (Pubitemid 32691636)
27. Frecha C, Toscano MG, Costa C, et al. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis. Gene Ther. 2008;15(12):930-941. (Pubitemid 351791480)
28. Frecha C, Szecsi J, Cosset FL, Verhoeyen E. Strategies for targeting lentiviral vectors. Curr Gene Ther. 2008;8(6):449-460.
29. Ting-De Ravin SS, Kennedy DR, Naumann N, et al. Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy. Blood. 2006;107(8):3091-3097.
30. DePolo NJ, Harkleroad CE, Bodner M, et al. The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J Virol. 1999;73(8):6708-6714. (Pubitemid 29327853)
31. Froelich S, Ziegler L, Stroup K, Wang P. Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors codisplaying stem cell factor and a fusogenic molecule. Biotechnol Bioeng. 2009;104(1):206-215.
32. Liang M, Pariente N, Morizono K, Chen IS. Targeted transduction of CD34+ hematopoietic progenitor cells in nonpurified human mobilized peripheral blood mononuclear cells. J Gene Med. 2009;11(3):185-196.
33. McCauslin CS, Wine J, Cheng L, et al. In vivo retroviral gene transfer by direct intrafemoral injection results in correction of the SCID phenotype in Jak3 knock-out animals. Blood. 2003;102(3):843-848. (Pubitemid 36917774)
34. Worsham DN, Schuesler T, von Kalle C, Pan D. In vivo gene transfer into adult stem cells in unconditioned mice by in situ delivery of a lentiviral vector. Mol Ther. 2006;14(4):514-524. (Pubitemid 44296095)
35. Marin M, Lavillette D, Kelly SM, Kabat D. N-linked glycosylation and sequence changes in a critical negative control region of the ASCT1 and ASCT2 neutral amino acid transporters determine their retroviral receptor functions. J Virol. 2003;77(5):2936-2945. (Pubitemid 36228078)
36. Green BJ, Lee CS, Rasko JE. Biodistribution of the RD114/mammalian type D retrovirus receptor, RDR. J Gene Med. 2004;6(3):249-259. (Pubitemid 40228042)
37. Cavazzana-Calvo M, Fischer A. Efficacy of gene therapy for SCID is being confirmed. Lancet. 2004;364(9452):2155-2156. (Pubitemid 40018431)
38. Marangoni F, Bosticardo M, Charrier S, et al. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther. 2009;17(6):1073-1082.
39. Galimi F, Noll M, Kanazawa Y, et al. Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. Blood. 2002;100(8):2732-2736.
40. Río P, Meza NW, Gonzalez-Murillo A, et al. In vivo proliferation advantage of genetically corrected hematopoietic stem cells in a mouse model of Fanconi anemia FA-D1. Blood. 2008;112(13):4853-4861.
41. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 2010;467(7313):318-322.
42. Miccio A, Cesari R, Lotti F, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U S A. 2008;105(30):10547-10552.
43. Gregory JJ Jr, Wagner JE, Verlander PC, et al. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci U S A. 2001;98(5):2532-2537. (Pubitemid 32209516)
44. Gross M, Hanenberg H, Lobitz S, et al. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res. 2002;98(2-3):126-135. (Pubitemid 37465006)
45. Mankad A, Taniguchi T, Cox B, et al. Natural gene therapy in monozygotic twins with Fanconi anemia. Blood. 2006;107(8):3084-3090.
46. Tulpule A, Lensch MW, Miller JD, et al. Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood. 2010;115(17):3453-3462.
47. Mátrai J, Chuah MK, VandenDriessche T. Preclinical and clinical progress in hemophilia gene therapy. Curr Opin Hematol. 2010;17(5):387-392.
48. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97(10):2962-2971.
49. Trobridge GD, Wu RA, Beard BC, et al. Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One. 2009;4(11):e7693.